Roth Capital Reiterates Buy On Lion Biotechnologiesl; Sees 196% Upside For The Stock
In a research report released this morning, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Lion Biotechnologies Inc. (LBIO) with a $20 price target, which represents a potential upside of 196% from where the stock is currently trading.
Pantginis commented: “Following a management update, our confidence in our underlying investment case on Lion has been bolstered. Specifically, the company has very broad and important background efforts ongoing, which we believe will result in 1) a commercial manufacturing procedure with reduced costs, 2) a defined registration path forward for melanoma, 3) defined path forward for additional tumor indications, 4) boosting long-term potential with next generation technologies and, importantly, 5) providing visibility to investors and potential partners for all of these initiatives”.
The analyst added, “As we look forward, we expect thefollowing catalysts: 1) finalizing of manufacturing process by the end of 2014,2) complete license for next generation T cells by end of 2014, 3) updatedPhase I data from NCI TIL combination with Zelboraf by end of 2014 (NCI), 4)opening of new R&D facility, 5) initiate Phase I anti-PD1 combination study inmelanoma (Moffitt), 6) Phase I data on ipilimumab combination study in 1Q15and 7) have technology in multiple tumor indications by end of 2015”.
According to TipRanks.com, analyst Joseph Pantginis currently has an average return of -7.6% and a 39% success rate. Pantginis is ranked #3125 out of 3182 analysts.